PPARGC1A and type 2 diabetes mellitus: Additionally, we highlight the miR-30d-5p/SIRT1/PGC-1α axis as a central pathway mediating these beneficial effects, suggesting that miR-30d-5p may serve as a potential therapeutic target for improving metabolic health in T2DM.